As a global leader in structural heart diseases, Edwards Lifesciences strongly supports the objectives of the EU Public Procurement Directive to improve quality access to healthcare technologies. After more than 10 years of application, and many challenges in its rightful execution, the revision of the EU Directive on Public Procurement provides an important opportunity to ensure that breakthrough implantable…
Edwards Lifesciences
Company · Switzerland · EU Transparency Register 908457634413-95
Counts here are a floor, never a total: they cover the 326 consultation files tracked so far (29,503 submissions, mostly 2025–26), so an organization's real filing history is larger, not smaller.
Who they are
Among the 925 companies & groups on this site, they rank #144 by legislative files engaged — a count of participation, not a measure of influence.
Declares membership of
- MedTech Europe →
- Friends of Europe
- AmCham EU
- European Patient Safety Foundation
- EU Structural Heart Disease Coalition →
- Informal Working Group on Capacity-Enhancing Innovations
Self-declared to the EU Transparency Register (snapshot 30 Aug 2026).
- Register category
- Companies & groups
- Head office
- Dilbeek, Belgium
Self-declared to the EU Transparency Register (snapshot 30 Aug 2026); cost bands are floors, not audited totals. Reused under Commission Decision 2011/833/EU.
Track Edwards in PolicySpeak: request access →
Work at Edwards Lifesciences? so we know who speaks for it.
Their record over time
Edwards Lifesciences filed 5 positions between 6 Mar 2025 and 19 May 2026, across 5 of the 326 legislative files tracked here, attaching a full position paper 5 times.
What they argued
Edwards Lifesciences, a global leader in breakthrough structural heart innovations investing 19% of annual revenues in breakthrough research & innovation, strongly welcomes the upcoming reform of the EU Medical Device Regulation process.
As a global leader in structural heart diseases, Edwards Lifesciences strongly supports the objectives of the EU Public Procurement Directive to improve quality access to healthcare technologies. After more than 10 years of application, and many challenges in its rightful execution, the revision of the EU Directive on Public Procurement provides an important opportunity to ensure that breakthrough implantable…
Edwards Lifesciences welcomes the proposal for the European Innovation Act as a timely and strategic initiative to accelerate the uptake of breakthrough innovation and strengthen Europes industrial competitiveness.
The recently adopted European Union Cardiovascular Health Safe Hearts Plan represents a critical step forward to tackle the burden of Europes leading cause of death, cardiovascular disease (CVD), including Structural Heart Disease (SHD).
Looking for an argument rather than an organization? Search every submission for a phrase and see everyone who used it.
Turns up on the same files
Organizations that also filed on at least two of the same consultations. A shared interest in the same dossiers — not evidence of coordination, and we do not suggest any.
- MedTech Europe · 5 files in common
- EFPIA · 4 files in common
- Siemens Healthineers · 4 files in common
- Royal Philips · 4 files in common
- EDF - Electricité de France · 3 files in common
Showing 5 of 198.
Is this your organization?
Everything on this page comes from Edwards Lifesciences’s own submissions to the European Commission — we have added nothing and interpreted nothing. If something is wrong or out of date, email info@policyspeak.com and we will correct it. If you are an individual named in a record, our privacy policy sets out your rights to correction, objection and removal.
Quotes are verbatim from submissions published by the European Commission, trimmed to their opening passage and never summarized by a model. Organizations only, never individuals. Reused under Commission Decision 2011/833/EU; the European Commission is not liable for this reuse.